| Decoy receptor3(DcR3) is found at the end of20th century anewly discovered tumor necrosis factor receptor. The expression level ofDcR3in lung,gastrointestinal tract tumor, brain malignant glioma, breastcancer, liver cancer and other malignant tumors is high. Its geneamplification and excessive expression is closely related to the occurrenceand development,immune escape mechanism of tumor.Currently, the studyof pancreatic cancer is more concentrated in death receptor DR4, DR5anddecoy receptor DcR1and DcR2，DcR3research is less. As application ofsiRNA (Small interfering RNA）interference technology, antisense RNAtechnology and DcR3monoclonal antibody technology and tumorvaccine technology, DcR3provides a new train of thought intumorigenesis, gene diagnosis, targeted therapy.Objective：This study uses tissue microarray technology,and takes decoyreceptor3protein as the research object, which closely related tomalignant tumor occurrence, development and transferrion.By tissuemicroarray and immunohistochemical methods, detect the espressiong ofDcR3in pancreatic cancer tissue.The statistical analysis of DcR3expressed in pancreatic cancer, will provides a new clue and way ofthinking for the treatment and prognosis judgement of pancreatic cancer. Methods：1、 The tissue microarrays comprised130cases of tissue ofpancreatic cancer patients from January2009to December2012in ourhospital, including40cases of pancreatic cancer tissue,15cases of tissueadjacent to carcinoma, and15cases of normal tissues, and The Thirdhospital of Peking University,xi ’an jiaotong university affiliatedhospital respectively provide cases,25cases and35cases of pancreaticcancer.then builded pancreatic tissue microarray.Using immunohistochemicalmethod (Envision method) to detect the expression levels of DcR3protein.2、Statistical analysis: analysis the differences of the expressionlevel of DcR3in several groups:pancreatic cancer patients’ age, gender,histologic grade, TNM stage, lymph node metastasis.Results：The positive rate of DcR3in pancreatic cancer tissue was86.00%(86/100),significantly higher than that in the adjaeent-tumor pancreaticcancer by46.6%(7/15, p=0.00) and13.3%of normal tissues (2/15, p=0.00); in clinical stage Ⅲ, The positive rate of DcR3was100%(35/35),significantly higher than that in TNM stageⅡ87%(36/41, p=0.033) and TNM stage Ⅰ62.5%(15/24, p=0.00);With lymph nodemetastasis,the DcR3positive rate was93.4%(43/46) is significantlyhigher than without lymph node metastasis group76.9%(43/54，p=0.047). In poorly differentiated pancreatic cancer tissues, the positive rate of DcR3protein is100%（31/31）,and higher than that in highlydifferentiation group64%（16/25，p=0.00）and moderately differentiatedgroup88.6%（39/44，p=0.052），There are differences between thegroups，p=0.00; The positive rate of DcR3in group which tumordiameter is greater than4cm was（83.1%）,and is not higher than that inthe group which tumor diameter is less than4cm（78.6%，P=1）.Theexpression of DcR3has nothing to do with age, sex, tumor diameter size.Conclusion：1. High expression of DcR3protein exists in the pancreatic tissue.In the ancreatic cancer tissue, the expression level of DcR3wasobviously higher than that of cancer adjacent tissues and normal tissues.The expression level of DcR3in the adjacent to carcinoma tissues wassignificantly higher than that in the normal tissue. From normal tissue,the tissue adjacent to carcinoma,to the pancreas tissue, the expressionlevel of DcR3protein is gradually rising.2. The expression level of DcR3protein is associated with clinicalstage, tissue differentiation degree and the presence of lymph nodemetastasis, has nothing to do with age, sex, tumor diameter size.3. Tissue microarray technology can be high flux and efficientlydetect the clinical tissue samples, has the characteristics of efficient,economic, time and energy. |
PDF Full Text Request